A week after Inovio Pharmaceuticals Inc. began testing its Zika vaccine, GLS-5700, in healthy volunteers, the National Institutes of Allergy and Infectious Diseases (NIAID) announced on Tuesday it has dosed the first patient in the phase I VRC 319 trial of its own Zika vaccine.

Selecta Bioscience Inc. published preclinical data this week suggesting its immune tolerance therapy SVP-Rapamycin (SEL-110), which is in a phase I trial to prevent the formation of antidrug antibodies (ADAs) to enzyme therapy for gout, could be broadly useful to prevent ADA formation to different types of biologics.

Antibodies aimed at the protein tau, which accumulates during the later stages of Alzheimer’s disease (AD), do not need to engage immune cells to clear the protein, and they were less toxic to neurons in cell culture experiments than antibodies that did bind to immune cells as well as tau.

A team from the University of Tuebingen has identified the first bactericidal compound produced by a member of the human microbiome.

Comprehensive health assessment of a group of 13 cloned sheep, including the "Nottingham Dollies," four sheep that were created from the same cell line as Dolly the Sheep, has shown that, as a group, the animals were no more prone to health problems than naturally conceived sheep of the same age.

Scientists from the NIH have identified mechanisms by which HIV persists in different anatomical locations.

DURBAN, South Africa – In the early days of the AIDS epidemic, the life expectancy for those diagnosed with HIV was two years from the time of diagnosis.